CG Oncology in the Spotlight
CG Oncology, Inc. (NASDAQ: CGON), a biopharmaceutical company at the forefront of developing innovative treatments for bladder cancer, has announced significant upcoming events aimed at enhancing engagement with investors. The company, known for its dedication to advancing a promising bladder-sparing therapeutic, is gearing up for pivotal fireside chats that will offer insights into their ongoing projects and future direction.
Key Conferences Scheduled
Cantor Global Healthcare Conference
The first of these important conferences is the Cantor Global Healthcare Conference, where Arthur Kuan, the company’s Chairman and CEO, will lead discussions. This event is scheduled for a presentation on a Friday in September, specifically at 10:20 AM ET, in New York City. The conference aims to foster dialogue around advancements in healthcare, and CG Oncology is poised to share their vision and developments within the bladder cancer treatment landscape.
Morgan Stanley Global Healthcare Conference
Following the Cantor Conference, the leadership team will also present at the Morgan Stanley 23rd Annual Global Healthcare Conference. This engagement takes place on another Tuesday in September, at 7:45 AM ET. At this event, Ambaw Bellete, President and COO, will also contribute to the discussions, emphasizing CG Oncology’s mission and its potential impact on patients.
Engaging the Investment Community
These conferences represent a critical opportunity for CG Oncology to connect with investors who are interested in the latest innovations in cancer therapies. The discussions led by their executives will delve into the therapeutic pipeline, addressing both scientific advancements and market potential. Interested parties will be able to access live audio webcasts of these presentations through the Investor Relations section of the CG Oncology website. These replays will be available for a period following the live events, ensuring that all stakeholders remain informed about the company’s developments.
About CG Oncology
CG Oncology is dedicated to transforming the lives of bladder cancer patients. Committed to innovative research and development, the company's mission encompasses not just delivering effective treatments but also enhancing the overall quality of life for affected individuals. Through the use of cutting-edge immunotherapy approaches, CG Oncology aims to create viable options that patients can trust. As they participate in these conferences, the commitment to pioneering therapeutic solutions remains clear.
Contact Information
For more information, CG Oncology encourages media and interested persons to reach out to the respective contact points:
Media Contact
Sarah Connors
Vice President, Communications and Patient Advocacy
Email: sarah.connors@cgoncology.com
Investor Relations
Megan Knight
Vice President, Investor Relations
Email: megan.knight@cgoncology.com
Frequently Asked Questions
What is CG Oncology's primary focus?
CG Oncology focuses on developing potential therapies for bladder cancer, aiming to innovate treatment options that preserve the bladder.
Who are the key executives participating in the conferences?
Arthur Kuan, Chairman & CEO, and Ambaw Bellete, President & COO, will represent CG Oncology at the upcoming investor conferences.
How can I access the conference presentations?
Live audio webcasts of the presentations will be available on the Investor Relations section of the CG Oncology website.
When are the important investor conferences?
CG Oncology will present at the Cantor Global Healthcare Conference on a Friday and at the Morgan Stanley Conference on a Tuesday in September.
What is CG Oncology's mission?
CG Oncology is dedicated to improving patient outcomes in bladder cancer through innovative therapeutic developments and enhanced quality of life initiatives.
